Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Langerhans Cell Histiocytosis
Explore 23 assets in Langerhans Cell Histiocytosis →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03210714CT.gov Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) | — | Active Not Recruiting | — | — | — |
NCT03155620CT.gov Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Langerhans Cell Histiocytosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 (this asset) | National Cancer Institute (NCI) | P2 | CCC · 53 |
| Melphalan | M.D. Anderson Cancer Center | P2 | B |
| Palbociclib | National Cancer Institute (NCI) | P2 | B |
| Olaparib | National Cancer Institute (NCI) | P2 | B |
| Tazemetostat | National Cancer Institute (NCI) | P2 | B |
| Rituximab | M.D. Anderson Cancer Center | P2 | B |
| Cyclophosphamide | M.D. Anderson Cancer Center | P2 | B |
| Busulfanum | M.D. Anderson Cancer Center | P2 | B |
| Clofarabine | M.D. Anderson Cancer Center | P2 | B |
+19 more in the Langerhans Cell Histiocytosis cohort
Other indications for Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P2 | B · 60 |
| Bladder Transitional Cell Carcinoma | — | P2 | B · 58 |
| Hepatocellular Carcinoma | — | P2 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 in Langerhans Cell Histiocytosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pan-fgfr-tyrosine-kinase-inhibitor-jnj-42756493-langerhans-cell-histiocytosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →